Cytosorbents (CTSO) EBIT Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.31% |
| Dec 31, 2025 | -10.73% |
| Sep 30, 2025 | -7.87% |
| Jun 30, 2025 | -1.85% |
| Mar 31, 2025 | -9.42% |
| Dec 31, 2024 | 8.97% |
| Sep 30, 2024 | 3.01% |
| Jun 30, 2024 | 0.33% |
| Mar 31, 2024 | -1.68% |
| Dec 31, 2023 | -10.99% |
| Sep 30, 2023 | -22.08% |
| Jun 30, 2023 | -9.39% |
| Mar 31, 2023 | -20.54% |
| Dec 31, 2022 | -10.81% |
| Sep 30, 2022 | -33.22% |
| Jun 30, 2022 | -29.09% |
| Mar 31, 2022 | -37.99% |
| Dec 31, 2021 | -15.91% |
| Sep 30, 2021 | -20.32% |
| Jun 30, 2021 | -12.88% |
| Mar 31, 2021 | -6.41% |
| Dec 31, 2020 | -3.53% |
| Sep 30, 2020 | 1.84% |
| Jun 30, 2020 | -8.16% |
| Mar 31, 2020 | 1.78% |
| Dec 31, 2019 | -13.44% |
| Sep 30, 2019 | -30.56% |
| Jun 30, 2019 | -21.63% |
| Mar 31, 2019 | -30.00% |
| Dec 31, 2018 | -40.94% |
| Sep 30, 2018 | -25.24% |
| Jun 30, 2018 | -24.38% |
| Mar 31, 2018 | -16.87% |
| Dec 31, 2017 | -36.16% |
| Sep 30, 2017 | -29.02% |
| Jun 30, 2017 | -18.22% |
| Mar 31, 2017 | -7.85% |
| Dec 31, 2016 | -36.39% |
| Sep 30, 2016 | -11.84% |
| Jun 30, 2016 | -19.25% |
| Mar 31, 2016 | -13.12% |
| Dec 31, 2015 | -36.05% |
| Sep 30, 2015 | -22.22% |
| Jun 30, 2015 | -26.92% |